Human papillomavirus type 16 does not require cathepsin L or B for infection

References

1. Akache B., Grimm D., Shen X., Fuess S., Yant S. R., Glazer D. S., Park J., Kay M. A. 2007; A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther 15:330–339 [View Article][PubMed]
   [Google Scholar]
2. Boukamp P., Petrussevska R. T., Breitkreutz D., Hornung J., Markham A., Fusenig N. E. 1988; Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761–771 [View Article][PubMed]
   [Google Scholar]
3. Campos S. K., Chapman J. A., Deymier M. J., Bronnimann M. P., Ozbun M. A. 2012; Opposing effects of bacitracin on human papillomavirus type 16 infection: enhancement of binding and entry and inhibition of endosomal penetration. J Virol 86:4169–4181 [View Article][PubMed]
   [Google Scholar]
4. Conus S., Simon H. U. 2010; Cathepsins and their involvement in immune responses. Swiss Med Wkly 140:w13042[PubMed]
   [Google Scholar]
5. Dabydeen S. A., Meneses P. I. 2009; The role of NH₄Cl and cysteine proteases in Human Papillomavirus type 16 infection. Virol J 6:109 [View Article][PubMed]
   [Google Scholar]
6. Day P. M., Baker C. C., Lowy D. R., Schiller J. T. 2004; Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A 101:14252–14257 [View Article][PubMed]
   [Google Scholar]
7. Deussing J., Roth W., Saftig P., Peters C., Ploegh H. L., Villadangos J. A. 1998; Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci U S A 95:4516–4521 [View Article][PubMed]
   [Google Scholar]
8. Ebert D. H., Deussing J., Peters C., Dermody T. S. 2002; Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J Biol Chem 277:24609–24617 [View Article][PubMed]
   [Google Scholar]
9. Forman D., de Martel C., Lacey C. J., Soerjomataram I., Lortet-Tieulent J., Bruni L., Vignat J., Ferlay J., Bray F.& other authors ( 2012; Global burden of human papillomavirus and related diseases. Vaccine 30:Suppl 5F12–F23 [View Article][PubMed]
   [Google Scholar]
10. Kaletsky R. L., Simmons G., Bates P. 2007; Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol 81:13378–13384 [View Article][PubMed]
    [Google Scholar]
11. Misasi J., Chandran K., Yang J. Y., Considine B., Filone C. M., Côté M., Sullivan N., Fabozzi G., Hensley L., Cunningham J. 2012; Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol 86:3284–3292 [View Article][PubMed]
    [Google Scholar]
12. Schelhaas M., Shah B., Holzer M., Blattmann P., Kühling L., Day P. M., Schiller J. T., Helenius A. 2012; Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog 8:e1002657 [View Article][PubMed]
    [Google Scholar]
13. Smith J. L., Campos S. K., Wandinger-Ness A., Ozbun M. A. 2008; Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. J Virol 82:9505–9512 [View Article][PubMed]
    [Google Scholar]
14. Turk V., Stoka V., Vasiljeva O., Renko M., Sun T., Turk B., Turk D. 2012; Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 1824:68–88 [View Article][PubMed]
    [Google Scholar]
15. Woodman C. B., Collins S. I., Young L. S. 2007; The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7:11–22 [View Article][PubMed]
    [Google Scholar]
16. zur Hausen H. 2002; Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350 [View Article][PubMed]
    [Google Scholar]